ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis
NASDAQ:ASTH - Nasdaq - US03763A2078 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to ASTH. ASTH was compared to 108 industry peers in the Health Care Providers & Services industry. ASTH has an average financial health and profitability rating. ASTH has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ASTH had positive earnings in the past year.
ASTH had a positive operating cash flow in the past year.
ASTH had positive earnings in 4 of the past 5 years.
Of the past 5 years ASTH 4 years had a positive operating cash flow.
1.2 Ratios
ASTH's Return On Assets of 4.86% is fine compared to the rest of the industry. ASTH outperforms 77.57% of its industry peers.
ASTH's Return On Equity of 8.86% is fine compared to the rest of the industry. ASTH outperforms 72.90% of its industry peers.
ASTH's Return On Invested Capital of 5.11% is fine compared to the rest of the industry. ASTH outperforms 61.68% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ASTH is in line with the industry average of 8.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.86% | ||
| ROE | 8.86% | ||
| ROIC | 5.11% |
ROA(3y)6.42%
ROA(5y)N/A
ROE(3y)11.12%
ROE(5y)N/A
ROIC(3y)7.41%
ROIC(5y)N/A
1.3 Margins
ASTH has a Profit Margin of 3.63%. This is in the better half of the industry: ASTH outperforms 75.70% of its industry peers.
ASTH's Profit Margin has declined in the last couple of years.
ASTH's Operating Margin of 4.92% is fine compared to the rest of the industry. ASTH outperforms 61.68% of its industry peers.
In the last couple of years the Operating Margin of ASTH has declined.
With a Gross Margin value of 15.09%, ASTH is not doing good in the industry: 71.03% of the companies in the same industry are doing better.
ASTH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.92% | ||
| PM (TTM) | 3.63% | ||
| GM | 15.09% |
OM growth 3Y-19.54%
OM growth 5YN/A
PM growth 3Y-7.38%
PM growth 5YN/A
GM growth 3Y-10.38%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASTH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
There is no outstanding debt for ASTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 4.16 indicates that ASTH is not in any danger for bankruptcy at the moment.
ASTH has a better Altman-Z score (4.16) than 80.37% of its industry peers.
ASTH has a debt to FCF ratio of 6.29. This is a slightly negative value and a sign of low solvency as ASTH would need 6.29 years to pay back of all of its debts.
The Debt to FCF ratio of ASTH (6.29) is better than 70.09% of its industry peers.
ASTH has a Debt/Equity ratio of 0.60. This is a neutral value indicating ASTH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.60, ASTH perfoms like the industry average, outperforming 55.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 6.29 | ||
| Altman-Z | 4.16 |
ROIC/WACC0.63
WACC8.13%
2.3 Liquidity
A Current Ratio of 1.91 indicates that ASTH should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.91, ASTH is in the better half of the industry, outperforming 70.09% of the companies in the same industry.
ASTH has a Quick Ratio of 1.91. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ASTH (1.91) is better than 71.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.91 |
3. Growth
3.1 Past
The earnings per share for ASTH have decreased strongly by -32.58% in the last year.
The Earnings Per Share has been growing by 19.19% on average over the past years. This is quite good.
EPS 1Y (TTM)-32.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-157.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%88.43%
3.2 Future
ASTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.87% yearly.
ASTH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.80% yearly.
EPS Next Y62.55%
EPS Next 2Y47.61%
EPS Next 3Y42.78%
EPS Next 5Y31.87%
Revenue Next Year34.25%
Revenue Next 2Y29.14%
Revenue Next 3Y18.65%
Revenue Next 5Y15.8%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 28.52, ASTH can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of ASTH is on the same level as its industry peers.
When comparing the Price/Earnings ratio of ASTH to the average of the S&P500 Index (29.43), we can say ASTH is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 17.54, the valuation of ASTH can be described as rather expensive.
Based on the Price/Forward Earnings ratio, ASTH is valued a bit cheaper than the industry average as 60.75% of the companies are valued more expensively.
ASTH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.67.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.52 | ||
| Fwd PE | 17.54 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as ASTH.
ASTH's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. ASTH is cheaper than 67.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.43 | ||
| EV/EBITDA | 18.61 |
4.3 Compensation for Growth
ASTH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ASTH's earnings are expected to grow with 42.78% in the coming years.
PEG (NY)0.46
PEG (5Y)1.49
EPS Next 2Y47.61%
EPS Next 3Y42.78%
5. Dividend
5.1 Amount
No dividends for ASTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
25.38
-9.3 (-26.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners47.59%
Inst Owner ChangeN/A
Ins Owners8.89%
Ins Owner Change-6.79%
Market Cap1.43B
Analysts85.56
Price Target63.34 (149.57%)
Short Float %3.88%
Short Ratio5.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend1.33
Dividend Growth(5Y)N/A
DP99.14%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.15%
Min EPS beat(2)0.55%
Max EPS beat(2)1.74%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)0.55%
Max EPS beat(4)71.85%
EPS beat(8)7
Avg EPS beat(8)19.76%
EPS beat(12)10
Avg EPS beat(12)21.43%
EPS beat(16)14
Avg EPS beat(16)29.22%
Revenue beat(2)2
Avg Revenue beat(2)4.83%
Min Revenue beat(2)1.5%
Max Revenue beat(2)8.16%
Revenue beat(4)3
Avg Revenue beat(4)1.73%
Min Revenue beat(4)-4.21%
Max Revenue beat(4)8.16%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.72%
PT rev (3m)-2.18%
EPS NQ rev (1m)-15.52%
EPS NQ rev (3m)-15.47%
EPS NY rev (1m)-0.41%
EPS NY rev (3m)-8.45%
Revenue NQ rev (1m)2.75%
Revenue NQ rev (3m)3.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.52 | ||
| Fwd PE | 17.54 | ||
| P/S | 0.83 | ||
| P/FCF | 20.43 | ||
| P/OCF | 17.32 | ||
| P/B | 2.03 | ||
| P/tB | 7.68 | ||
| EV/EBITDA | 18.61 |
EPS(TTM)0.89
EY3.51%
EPS(NY)1.45
Fwd EY5.7%
FCF(TTM)1.24
FCFY4.9%
OCF(TTM)1.47
OCFY5.78%
SpS30.62
BVpS12.53
TBVpS3.3
PEG (NY)0.46
PEG (5Y)1.49
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.86% | ||
| ROE | 8.86% | ||
| ROCE | 8.72% | ||
| ROIC | 5.11% | ||
| ROICexc | 7.98% | ||
| ROICexgc | 48.09% | ||
| OM | 4.92% | ||
| PM (TTM) | 3.63% | ||
| GM | 15.09% | ||
| FCFM | 4.06% |
ROA(3y)6.42%
ROA(5y)N/A
ROE(3y)11.12%
ROE(5y)N/A
ROIC(3y)7.41%
ROIC(5y)N/A
ROICexc(3y)12.09%
ROICexc(5y)N/A
ROICexgc(3y)52.51%
ROICexgc(5y)N/A
ROCE(3y)12.64%
ROCE(5y)N/A
ROICexcg growth 3Y21.3%
ROICexcg growth 5YN/A
ROICexc growth 3Y3.5%
ROICexc growth 5YN/A
OM growth 3Y-19.54%
OM growth 5YN/A
PM growth 3Y-7.38%
PM growth 5YN/A
GM growth 3Y-10.38%
GM growth 5YN/A
F-Score5
Asset Turnover1.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 6.29 | ||
| Debt/EBITDA | 3.87 | ||
| Cap/Depr | 50.83% | ||
| Cap/Sales | 0.73% | ||
| Interest Coverage | 3.05 | ||
| Cash Conversion | 75.32% | ||
| Profit Quality | 111.9% | ||
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.91 | ||
| Altman-Z | 4.16 |
F-Score5
WACC8.13%
ROIC/WACC0.63
Cap/Depr(3y)133.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.18%
Cap/Sales(5y)N/A
Profit Quality(3y)90.19%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-157.69%
EPS Next Y62.55%
EPS Next 2Y47.61%
EPS Next 3Y42.78%
EPS Next 5Y31.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%88.43%
Revenue Next Year34.25%
Revenue Next 2Y29.14%
Revenue Next 3Y18.65%
Revenue Next 5Y15.8%
EBIT growth 1Y-18.85%
EBIT growth 3Y1.67%
EBIT growth 5YN/A
EBIT Next Year63.3%
EBIT Next 3Y35.99%
EBIT Next 5Y26.11%
FCF growth 1Y-32.93%
FCF growth 3Y-4.09%
FCF growth 5YN/A
OCF growth 1Y-16.93%
OCF growth 3Y13.91%
OCF growth 5YN/A